# Oobli

自称是首家也是唯一一家实现商业规模化的甜蛋白技术平台；于2025年9月因其基于布拉泽因的甜味剂成分获得第三封FDA"无异议函"，并于2026年4月宣布与正从制糖业向高价值分子多元化转型的制糖企业Magdalena达成安第斯地区生产合作。

Source: https://cn.bioecon.ru/companies/oobli/
Updated: 2026-08-15

- 国家: United States

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 迄今累计融资约4,300万至5,000万美元 | https://oobli.com/blogs/news/oobli-and-ingredion-announce-partnership-as-demand-for-sweet-proteins-accelerates, https://www.caplight.com/company/oobli |
| 生产基地 | 研究实验室位于加州戴维斯；生产在加州洛杉矶的合同代工厂进行 | https://www.wyomingnews.com/features/calif-startup-releases-unique-sweet-tea-here-s-what-makes-it-different/article_fef353bc-3ba9-11ee-9eaf-93dba7b429a7.html |
| 认证 | 获得3封FDA GRAS“无异议”函；多种蛋白具有自我认定的FDA GRAS地位；一种蛋白具有FEMA GRAS地位 | https://oobli.com/blogs/news/oobli-and-ingredion-announce-partnership-as-demand-for-sweet-proteins-accelerates, https://oobli.com/pages/regulatory, https://oobli.com/pages/sweet-protein-ingredients-for-food-and-beverage-brands |
| 监管批准 | 已收到三封FDA“无异议”函（截至2025年9月） | https://oobli.com/blogs/news/oobli-receives-third-no-questions-letter-from-the-fda-for-use-of-novel-sweet-protein-as-a-sweetening-ingredient, https://oobli.com/pages/sweet-protein-ingredients-for-food-and-beverage-brands, https://www.prnewswire.com/news-releases/oobli-receives-third-no-questions-letter-from-the-fda-for-use-of-novel-sweet-protein-as-a-sweetening-ingredient-302566197.html, https://www.proteinproductiontechnology.com/post/oobli-earns-third-fda-no-questions-letter-for-its-sweet-protein-platform-expanding-sugar-free-innovation |
| 员工人数 | 约42-45名员工 [中等置信度] | https://bouncewatch.com/company/oobli, https://prospeo.io/c/oobli, https://www.datanyze.com/companies/oobli/566133951 |
| 营收 | 估计每年介于 3.8M 至 39.7M 美元之间 [中等置信度] | https://prospeo.io/c/oobli, https://www.datanyze.com/companies/oobli/566133951 |

独立来源: bouncewatch.com, caplight.com, datanyze.com, prnewswire.com, prospeo.io, proteinproductiontechnology.com, wyomingnews.com

## 技术

- [甜蛋白（布拉泽因、索马甜、莫内林）](https://cn.bioecon.ru/technology/sweet-proteins-brazzein-thaumatin-monellin/)